Incretin‐Based Drugs and Risk of Intestinal Obstruction Among Patients With Type 2 Diabetes
| العنوان: | Incretin‐Based Drugs and Risk of Intestinal Obstruction Among Patients With Type 2 Diabetes |
|---|---|
| المؤلفون: | Christel Renoux, Hui Yin, Oriana Hoi Yun Yu, Astrid Herrero, Romain Altwegg, Jean-Luc Faillie, Laurent Azoulay |
| المصدر: | Clinical Pharmacology & Therapeutics. 111:272-282 |
| بيانات النشر: | Wiley, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Male, medicine.medical_specialty, Incretin, Type 2 diabetes, Incretins, Gastroenterology, Glucagon-Like Peptide-1 Receptor, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Odds Ratio, medicine, Humans, Hypoglycemic Agents, Pharmacology (medical), 030212 general & internal medicine, Propensity Score, Adverse effect, Sodium-Glucose Transporter 2 Inhibitors, Aged, Proportional Hazards Models, Pharmacology, Dipeptidyl-Peptidase IV Inhibitors, business.industry, Proportional hazards model, Incidence, Hazard ratio, Number needed to harm, Middle Aged, medicine.disease, United Kingdom, Confidence interval, 3. Good health, Diabetes Mellitus, Type 2, Propensity score matching, Female, 030211 gastroenterology & hepatology, business, Intestinal Obstruction |
| الوصف: | Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors might increase the risk of intestinal obstruction, but real-world evidence for this severe adverse event is lacking. Thus, the objective of this study was to determine whether GLP-1 RAs and DPP-4 inhibitors are associated with an increased risk of intestinal obstruction compared with sodium-glucose cotransporter-2 (SGLT-2) inhibitors. We used the United Kingdom Clinical Practice Research Datalink and linked databases to assemble two new-user, active comparator cohorts (2013-2019). The first included 25,617 and 67,261 GLP-1 RA and SGLT-2 inhibitor users, respectively. The second included 131,927 and 40,615 DPP-4 inhibitor and SGLT-2 inhibitor users, respectively. Propensity score fine stratification weighted Cox proportional hazards models were fit to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) of intestinal obstruction requiring hospitalization. GLP-1 RAs were associated with an increased risk of intestinal obstruction compared with SGLT-2 inhibitors (1.9 vs. 1.1 per 1,000 person-years, respectively; HR: 1.69, 95% CI: 1.04-2.74). The highest HR was observed after 1.6 years of use (HR: 3.48, 95% CI: 1.79-6.79). DPP-4 inhibitors were also associated with an increased risk (2.7 vs. 1.0 per 1,000 person-years; HR: 2.59, 95% CI: 1.52-4.42), with the highest HR observed after 1.8 years of use (HR: 9.53, 95% CI: 4.47-20.30). The number needed to harm after 1 year of use was 1,223 and 603 for GLP-1 RAs and DPP-4 inhibitors, respectively. In this large real-world study, GLP-1 RAs and DPP-4 inhibitors were associated with an increased risk of intestinal obstruction. |
| تدمد: | 1532-6535 0009-9236 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b70ff6869ba39e85cc4e9fe639b5fb6Test https://doi.org/10.1002/cpt.2430Test |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....2b70ff6869ba39e85cc4e9fe639b5fb6 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15326535 00099236 |
|---|